Pharmena

Pharmena P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Pharmena (PHR.WA) as of Oct 16, 2026 is -14.35. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -15.45 — a change of -7.12% (higher).

P/CF

-14.35

YoY

-7.12%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Pharmena is 2025 -14.35 . P/CF (Price-to-Cash-Flow Ratio) of Pharmena was 2024 -15.45 . It decreases by -7.12% higher compared to the previous year.

The Pharmena P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
10.82 PLN
Jan 1, 2019
-2.97 PLN
Jan 1, 2020
-17.43 PLN
Jan 1, 2021
-12.12 PLN
Jan 1, 2022
21.49 PLN
Jan 1, 2023
1.18 PLN
Jan 1, 2024
-15.45 PLN
Jan 1, 2025
-14.35 PLN
The Pharmena P/CF history
YEARP/CFYoY
-14.35-7.12%
-15.45-1,405.10%
1.18-94.49%
21.49-277.30%
-12.12-30.45%
-17.43+486.09%
-2.97-127.48%
10.82-82.87%
63.16-253.47%
-41.15+339.47%
-9.36+37.75%
-6.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmena Stock analysis

What does Pharmena do? Pharmena SA is a company based in Lodz, Poland, operating within the Consumer Staples sector, specifically in the Consumer products industry. The company has 24 employees and went public on August 25, 2008. Pharmena SA develops and markets products based on a patented active substance called 1-MNA, which is described as physiological and natural. The company's product range includes Dermena, a line targeting hair loss; Dermena Plus, a shampoo designed to reduce dandruff symptoms and prevent excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care; Thermi, a gel for treating thermal burns and sunburns; and Revium, a line of anti-wrinkle treatments. Pharmena SA collaborates with research centers across Europe, the United States, and Canada on multidirectional research and application studies. The company maintains a wholly owned subsidiary, Cortria Corporation, which is based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in Pharmena SA, and Pelion SA is identified as the main shareholder. The company's website is www.pharmena.eu. Pharmena is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmena stock

P/CF (Price-to-Cash-Flow Ratio) of Pharmena is -14.35 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Pharmena changed from -15.45 to -14.35, representing a -7.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Pharmena since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Pharmena with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Pharmena

All Key Metrics — Pharmena